Openbookopenbook
Equity
Abeona Therapeutics Inc(ABEO)
USD --+0.00%
Reward68High
Risk51Moderate
📊75%Data
Strong 1223% profit margin · Revenue down 100% YoY
ABEO
+0.0 · +0.00%
USD · NASDAQ
Abeona Therapeutics Inc | Healthcare
Growth Machine
Market Cap:335.61M
ℹ️
Reward Rating
68
High
Top 25% (model universe)
75% data coverage
ℹ️
Risk Rating
51
Moderate
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on ABEO to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: $19.57.

What is Abeona Therapeutics Inc?

, a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States.

ABEO · Verdict

Solid reward · elevated risk

ABEO stands out on growth and balance sheet, but watch the cash flow signal.

Based on 88% data coverage

ABEO · Verdict

What’s working & what to watch

Strengths 2

  • Growth93/100

    Revenue +60.3% CAGR

  • Balance sheet76/100

    Current ratio 6.93

Watchouts 3

  • Cash flow35/100

    -1448% free-cash-flow margin

  • Volatility35/100

    Below average

  • Valuation41/100

    P/E 526.3×

Model-based scoring. For information only — not financial advice.

What is Abeona Therapeutics Inc?

, a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 335.61M, and a P/E ratio of 5.8x.

Financial Highlights

Investment Breakdown

📈 Growth
Revenue and earnings growing steadily, indicating improving operating performance.
💰 Profitability
Adequate profitability with some margin variability in recent periods.
⚠️ Risk
Risk profile appears balanced versus broad market conditions.
💸 Valuation
Valuation appears fair relative to current fundamentals.

OpenBook Logo Analysis

Reward: High (68)

The scoring profile indicates moderate reward potential, with growth and profitability as the leading contributors. Risk indicators are elevated — volatility and macro sensitivity warrant consideration.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap335.61M
P/E Ratio5.8416
Dividend YieldN/A
52 Week High7.5401
52 Week Low4
Last AnnualDecember
IPO Date9/19/1980
IncorporatedUSA
Shares Outstanding57M
No. of Employees226
IndustryBiotechnology
ExchangeNASDAQ
Beta1.339
CurrencyUSD
Websitewww.abeonatherapeutics.com
openbook

Stock research for everyday UK investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.